Neoadjuvant Nivolumab plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The activity and safety of neoadjuvant nivolumab plus gemcitabine/cisplatin (N+GC) were tested in patients with muscle-invasive bladder urothelial carcinoma (MIBC). Materials and Methods In a prospective phase II trial, patients with cT2-T4a N0 MIBC who were eligible for cisplatin and medically appropriate to undergo radical cystectomy (RC) were enrolled. Treatment with nivolumab 3 mg/kg on days 1 and 15 plus GC (cisplatin 70 mg/m2 on day 1, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15) was repeated every 28 days up to 3 or 4 cycles, depending on the surgery schedules. The primary endpoint was pathologic complete response (pCR, ypT0). Secondary endpoints included pathologic downstaging (≤ ypT1), disease-free survival (DFS), and safety. Results Between September 2019 and October 2020, 51 patients were enrolled. Neoadjuvant N+GC was well tolerated. Among 49 patients who completed neoadjuvant N+GC, clinical complete response (cCR) was achieved in 59% of intent-to-treat (ITT) population. RC was performed in 34 (69%) patients. pCR was achieved in 24% (12/49) of ITT population and 35% (12/34) of RC patients. Median DFS was not reached. Over a median follow-up of 24 months, 12 patients experienced disease recurrence and were treated with palliative therapy or surgery. Although 12 patients declined surgery and were treated with concurrent chemoradiotherapy, DFS was longer in patients with cCR after neoadjuvant therapy than those without. Preoperative programmed death-ligand 1 (PD-L1) did not correlate with pCR or pathologic downstaging rates. Conclusion Neoadjuvant N+GC was feasible and provided meaningful pathologic responses in patients with MIBC, regardless of baseline PD-L1 expression (ONO-4538-X41; CRIS.nih.go.kr, KCT0003804).
Abstract
Purpose The activity and safety of neoadjuvant nivolumab plus gemcitabine/cisplatin (N+GC) were tested in patients with muscle-invasive bladder urothelial carcinoma (MIBC). Materials and Methods In a prospective phase II trial, patients with cT2-T4a N0 MIBC who were eligible for cisplatin and medically appropriate to undergo radical cystectomy (RC) were enrolled. Treatment with nivolumab 3 mg/kg on days 1 and 15 plus GC (cisplatin 70 mg/m2 on day 1, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15) was repeated every 28 days up to 3 or 4 cycles, depending on the surgery schedules. The primary endpoint was pathologic complete response (pCR, ypT0). Secondary endpoints included pathologic downstaging (≤ ypT1), disease-free survival (DFS), and safety. Results Between September 2019 and October 2020, 51 patients were enrolled. Neoadjuvant N+GC was well tolerated. Among 49 patients who completed neoadjuvant N+GC, clinical complete response (cCR) was achieved in 59% of intent-to-treat (ITT) population. RC was performed in 34 (69%) patients. pCR was achieved in 24% (12/49) of ITT population and 35% (12/34) of RC patients. Median DFS was not reached. Over a median follow-up of 24 months, 12 patients experienced disease recurrence and were treated with palliative therapy or surgery. Although 12 patients declined surgery and were treated with concurrent chemoradiotherapy, DFS was longer in patients with cCR after neoadjuvant therapy than those without. Preoperative programmed death-ligand 1 (PD-L1) did not correlate with pCR or pathologic downstaging rates. Conclusion Neoadjuvant N+GC was feasible and provided meaningful pathologic responses in patients with MIBC, regardless of baseline PD-L1 expression (ONO-4538-X41; CRIS.nih.go.kr, KCT0003804).
참고문헌 (30)
- Flaig TW, "Bladder cancer, version 3. 2020, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 18, pp.329~354 (2020)
- Witjes JA, "European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer : summary of the 2020 guidelines", Eur Urol, 79, pp.82~104 (2021)
- Raj GV, "Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer", Cancer, 117, pp.276~282 (2011)
- Advanced Bladder Cancer Meta-analysis Collaboration, "Neoadjuvant chemotherapy in invasive bladder cancer : update of a systematic review and meta-analysis of individual patient data advanced bladder cancer(ABC)meta-analysis collaboration", Eur Urol, 48, pp.202~205 (2005)
- Petrelli F, "Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy : a meta-analysis", Eur Urol, 65, pp.350~357 (2014)
- Sonpavde G, "Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy", Cancer, 115, pp.4104~4109 (2009)
- Sonpavde G, "Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer", J Urol, 185, pp.456~461 (2011)
- Sonpavde G, "PD-1 and PD-L1 inhibitors as salvage therapy for urothelial carcinoma", N Engl J Med, 376, pp.1073~1074 (2017)
- Necchi A, "Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma(PURE-01) : an open-label, single-arm, phase II study", J Clin Oncol, 36, pp.3353~3360 (2018)
- Powles T, "Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial", Nat Med, 25, pp.1706~1714 (2019)
- Galsky MD, "Atezolizumab with or without chemotherapy in metastatic urothelial cancer(IMvigor130) : a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 395, pp.1547~1557 (2020)
- Powles T, "Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma(KEYNOTE-361) : a randomi-sed, open-label, phase 3 trial", Lancet Oncol, 22, pp.931~945 (2021)
- Sharma P, "Nivolumab in metastatic urothelial carcinoma after platinum therapy(CheckMate 275) : a multicentre, single-arm, phase 2 trial", Lancet Oncol, 18, pp.312~322 (2017)
- Kanda S, "Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer : a four arms phase Ib study", Ann Oncol, 27, pp.2242~2250 (2016)
- Galsky MD, "Treatment of patients with metastatic urothelial cancer"unfit"for cisplatin-based chemotherapy", J Clin Oncol, 29, pp.2432~2438 (2011)
- 성현환, "Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder", Investigative and Clinical Urology, 63(2), pp.168~174 (2022), 대한비뇨의학회[DOI]
- 조장호, "Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy Followed by Radical Cystectomy: A Single-Center Retrospective Study", Journal of Urologic Oncology, 18(3), pp.194~200 (2020), 대한비뇨기종양학회[DOI]
- van Dijk N, "Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer : the NABUCCO trial", Nat Med, 26, pp.1839~1844 (2020)
- Rose TL, "Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer", J Clin Oncol, 39, pp.3140~3148 (2021)
- Galsky MD, "Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer(MIBC) : HCRN GU 16-257", J Clin Oncol, 39(15 Suppl), pp.4503~ (2021)
- Gupta S, "Results from BLASST-1(Bladder Cancer Signal Seeking Trial)of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer(MIBC)undergoing cystectomy", J Clin Oncol, 38(6 Suppl), pp.439~ (2020)
- Bajorin DF, "Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma", N Engl J Med, 384, pp.2102~2114 (2021)
- Liu J, "Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease", Cancer Discov, 6, pp.1382~1399 (2016)
- Friedman J, "Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen-specific T cells", Clin Cancer Res, 26, pp.679~689 (2020)
- Peyton CC, "Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer", JAMA Oncol, 4, pp.1535~1542 (2018)
- Chang E, "Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy : a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop", Nat Rev Urol, 19, pp.37~46 (2022)
- Niegisch G, "Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?", Curr Opin Urol, 21, pp.434~439 (2011)
- Martins I, "Liquid biopsies : applications for cancer diagnosis and monitoring", Genes(Basel), 12, pp.349~ (2021)
- Bellmunt J, "Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma(IMvigor010) : a multicentre, open-label, randomised, phase 3 trial", Lancet Oncol, 22, pp.525~537 (2021)
- Powles T, "ctDNA guiding adjuvant immunotherapy in urothelial carcinoma", Nature, 595, pp.432~437 (2021)